SLDB vs. RXRX
SLDB (Solid Biosciences Inc.) and RXRX (Recursion Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — SLDB in Drug Manufacturers - Specialty & Generic, RXRX in Biotechnology. Over the past 5 years, SLDB returned -34.20%/yr vs -35.38%/yr for RXRX. At a 0.37 correlation, their price movements are largely independent.
Performance
SLDB vs. RXRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SLDB achieves a 18.79% return, which is significantly higher than RXRX's -18.95% return.
SLDB
- 1D
- -7.46%
- 1M
- -6.94%
- YTD
- 18.79%
- 6M
- 16.12%
- 1Y
- 57.65%
- 3Y*
- 1.70%
- 5Y*
- -34.20%
- 10Y*
- —
RXRX
- 1D
- -12.76%
- 1M
- -3.35%
- YTD
- -18.95%
- 6M
- -29.62%
- 1Y
- -27.46%
- 3Y*
- -27.31%
- 5Y*
- -35.38%
- 10Y*
- —
SLDB vs. RXRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
SLDB Solid Biosciences Inc. | 18.79% | 41.00% | -34.85% | 14.13% | -79.50% | -65.28% |
RXRX Recursion Pharmaceuticals, Inc. | -18.95% | -39.50% | -31.44% | 27.89% | -54.99% | -45.27% |
Correlation
The correlation between SLDB and RXRX is 0.48, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.48 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.41 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.37 |
Correlation (All Time) Calculated using the full available price history since Apr 19, 2021 | 0.37 |
The correlation between SLDB and RXRX shifts across timeframes, from 0.37 (5 years) to 0.48 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
SLDB:
-$2.71
RXRX:
-$1.17
SLDB:
$0.00
RXRX:
$66.29M
SLDB:
-$853.00K
RXRX:
-$22.83M
SLDB:
-$190.68M
RXRX:
-$505.90M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SLDB vs. RXRX — Risk / Return Rank
SLDB
RXRX
SLDB vs. RXRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Solid Biosciences Inc. (SLDB) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| SLDB | RXRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.09 | ||
| Sortino ratioReturn per unit of downside risk | +1.66 | ||
| Omega ratioGain probability vs. loss probability | 1.18 | 0.99 | +0.19 |
| Calmar ratioReturn relative to maximum drawdown | 1.30 | -0.47 | +1.78 |
| Martin ratioReturn relative to average drawdown | 3.24 | -0.78 | +4.02 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| SLDB | RXRX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.72 | -0.37 | +1.09 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.37 | -0.38 | +0.01 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.34 | -0.38 | +0.03 |
Drawdowns
SLDB vs. RXRX - Drawdown Comparison
The maximum SLDB drawdown since its inception was -99.76%, which is greater than RXRX's maximum drawdown of -93.13%. Use the drawdown chart below to compare losses from any high point for SLDB and RXRX.
Loading charts...
Drawdown Indicators
| SLDB | RXRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.76% | -93.13% | -6.63% |
Max Drawdown (1Y)Largest decline over 1 year | -44.41% | -58.17% | +13.76% |
Max Drawdown (3Y)Largest decline over 3 years | -82.92% | -82.09% | -0.83% |
Max Drawdown (5Y)Largest decline over 5 years | -96.93% | -93.13% | -3.80% |
Current DrawdownCurrent decline from peak | -99.14% | -91.98% | -7.16% |
Average DrawdownAverage peak-to-trough decline | -87.69% | -75.37% | -12.32% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.82% | 35.43% | -17.61% |
Volatility
SLDB vs. RXRX - Volatility Comparison
The current volatility for Solid Biosciences Inc. (SLDB) is 23.26%, while Recursion Pharmaceuticals, Inc. (RXRX) has a volatility of 24.76%. This indicates that SLDB experiences smaller price fluctuations and is considered to be less risky than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SLDB | RXRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 23.26% | 24.76% | -1.50% |
Volatility (6M)Calculated over the trailing 6-month period | 58.03% | 46.84% | +11.19% |
Volatility (1Y)Calculated over the trailing 1-year period | 81.24% | 74.19% | +7.05% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 92.14% | 93.70% | -1.56% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 109.06% | 93.79% | +15.27% |
Dividends
SLDB vs. RXRX - Dividend Comparison
Neither SLDB nor RXRX has paid dividends to shareholders.
Financials
SLDB vs. RXRX - Financials Comparison
This section allows you to compare key financial metrics between Solid Biosciences Inc. and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
SLDB and RXRX have a correlation of 0.48, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
RXRX has higher volatility (24.76%) compared to SLDB (23.26%). In terms of maximum drawdown, SLDB dropped -99.76% vs RXRX's -93.13%.
SLDB currently has the higher Sharpe Ratio (0.72 vs -0.37), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SLDB and RXRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer